Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O43852

UPID:
CALU_HUMAN

ALTERNATIVE NAMES:
Crocalbin; IEF SSP 9302

ALTERNATIVE UPACC:
O43852; B3KPG9; D6QS48; D6QS49; D6QS50; D6QS51; D6QS52; D6QS53; D6QS54; D6QS55; D6QS56; D6QS57; D6QS58; D6QS59; F5H1Q9; F5H879; O60456; Q6FHB9; Q96RL3; Q9NR43

BACKGROUND:
The protein Calumenin, also referred to as Crocalbin or IEF SSP 9302, is integral to the regulation of vitamin K-dependent processes, specifically the carboxylation of glutamate residues. It acts by inhibiting the enzyme gamma-carboxylase GGCX and is known to bind calcium ions, albeit with low affinity. This suggests its significant yet nuanced role in calcium homeostasis and blood coagulation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Calumenin offers a promising avenue for the development of novel therapeutic approaches. Its critical role in enzymatic regulation and calcium signaling presents it as a potential target for interventions in diseases related to blood coagulation and calcium dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.